All timely result earnings PR IR governance ASR invitation Other Release others
-
2023/11/13
Takara Bio Announces "SonuAAV™", a Novel AAV Vector for Efficient Gene Transfer to the Inner Ear Organ.
-
2023/10/12
Construction of the Center for Gene and Cell Processing III, which manufactures mRNA vaccine ingredients and enzymes for mRNA production
-
2023/10/05
Takara Bio Announces Publication of Results from NY-ESO-1・siTCR™ Gene Therapy Study in Clinical Cancer Research
-
2023/10/03
Takara Bio Announces Presentation of Comparability Studies for
CD19 JAK/STAT CAR-T Cell Technology Transfer
-
2023/09/25
Takara Bio enters into a license agreement of RetroNectin®
with Fondazione Telethon ETS
読む Takara Bio enters into a license agreement of RetroNectin® with Fondazione Telethon ETS
-
2023/08/01
Started using refrigerated boxes for transportation with consideration for the environment
読む Started using refrigerated boxes for transportation with consideration for the environment
-
2023/05/29
Takara Bio Announces Poster Presentation of Data from Clinical Trial of NY-ESO-1・siTCR™ Gene Therapy at ASCO2023
-
2023/04/19
Indian subsidiary acquires ISO13485 certification
-
2023/04/04
Takara Bio Announces Initiation of Clinical Trial for Next-Generation CAR-T therapy
読む Takara Bio Announces Initiation of Clinical Trial for Next-Generation CAR-T therapy
-
2022/11/10
Announcement of Termination of Co-Development and Exclusive Marketing Agreements with Otsuka Pharmaceutical Co., Ltd. for NY-ESO-1・siTCR™ gene therapy candidate
-
2022/09/08
Launched CDMO service for gene therapy products
using siTCR® technology or JAK/STAT technology
読む Launched CDMO service for gene therapy products using siTCR® technology or JAK/STAT technology
-
2022/07/22
Launched a CDMO service using CereAAV™,
a brain-tropic AAV vector for gene therapy
読む Launched a CDMO service using CereAAV™, a brain-tropic AAV vector for gene therapy
-
2022/06/01
Takara Bio to Present Clinical Data from Investigator-Initiated Trial in Canada of NY-ESO-1・siTCR™ Gene Therapy at ASCO2022
【Poster Posted】
-
2022/04/25
Takara Bio Announces a Novel Brain-Tropic AAV Vector "CereAAV™" for Gene Therapy
読む Takara Bio Announces a Novel Brain-Tropic AAV Vector "CereAAV™" for Gene Therapy
-
2021/12/02
Implementation of the Center for Gene and Cell Processing to Respond to Diverse Modalities and Develop Supply Chains
-
2021/11/09
Announcement of Termination of Co-Development and Exclusive Marketing Agreements with Otsuka Pharmaceutical Co., Ltd. for Oncolytic virus HF10 and CD19-targeted CAR Gene Therapies
-
2021/06/21
Takara Bio enters into a license and supply agreement of RetroNectin® with BioNTech Cell & Gene Therapies GmbH
-
2021/02/01
Takara Bio Acquires ISO13485 Certification
-
2020/06/24
Clinical program for NY-ESO-1・siTCR(TM) gene therapy candidate receives designation in Japan as Orphan Regenerative Medicine
-
2020/03/06
Takara Bio to Support Development of Novel Coronavirus VaccineUndertaken by Osaka University Group
-
2020/01/21
Takara Bio Launches a New Facility for the Research and Manufacturing of Regenerative Medicine Products
-
2020/01/16
Takara Bio and Tmunity Enter into License Agreement to Advance siRNA Technology to Improve T cell Therapies
-
2019/09/24
Takara Bio to Present Clinical Data of Oncolytic Virus C-REV
and NY-ESO-1・siTCR Gene Therapy at ESMO 2019
-
2019/05/16
Takara Bio to Present Clinical Data of Oncolytic Virus C-REV and NY-ESO-1・siTCR Gene Therapy at ASCO 2019
-
2019/05/07
A wholly-owned subsidiary, Takara Biotechnology (Dalian) Co., Ltd.
Acquires ISO:13485 certification
-
2019/04/26
Takara Bio to Acquire an Exclusive License to Use Patent Technology Relating to New Generation CAR Gene Therapy
-
2019/04/26
Joint Research on New Development of CAR Gene Therapy
with Mie University
読む Joint Research on New Development of CAR Gene Therapy with Mie University
-
2019/04/24
Joint Research on Novel Approach to Cancer Immune and Gene Therapy
with Department of Immunotherapeutics, The University of Tokyo Hospital
-
2019/04/03
Takara Bio Submits Drug Master File to the U.S. FDA for
RetroNectin® GMP grade (Solution Type)
読む Takara Bio Submits Drug Master File to the U.S. FDA for RetroNectin® GMP grade (Solution Type)
-
2019/02/15
Designation Description Change of NY-ESO-1・siTCR gene therapy product under “SAKIGAKE Designation System”
-
2019/01/16
Takara to Present Oncolytic Virus C-REV Preliminary Data from the Phase I trial Targeting Unresectable Pancreatic Cancer at ASCO-GI 2019 Congress
-
2018/10/22
Announcement of Participation in AMED Project “Research and development of core technologies for gene and cell therapy”
-
2018/10/19
Oncolytic Virus C-REV Data Presentation of Phase II trial Targeting Unresectable or Metastatic Melanoma in Japan at ESMO 2018 Congress
-
2018/10/15
CAP-LAP Certification of Clinical Testing Laboratory for Takara Bio's Cancer Genetic Testing Business conducted in Osaka University Hospital
-
2018/09/03
Out-licensing agreement for commercial use of RetroNectin® into Daiichi Sankyo
読む Out-licensing agreement for commercial use of RetroNectin® into Daiichi Sankyo
-
2018/07/26
Takara Bio granted manufacturing license from the Swedish Medical Product Agency for clinical-grade human embryonic stem cell line derivation and banking
-
2018/05/31
Takara Bio presents HF10 Phase II clinical trial data at American Society of Clinical Oncology
読む Takara Bio presents HF10 Phase II clinical trial data at American Society of Clinical Oncology
-
2018/04/09
Takara Bio entered into an agreement for co-development/exclusive sales of NY-ESO-1・siTCR and CD19 CAR gene therapy with Otsuka
-
2018/04/06
Announcement on product designation of NY-ESO-1・siTCR gene therapy product for synoviral sarcoma under “SAKIGAKE Designation System” by the Ministry of Health, Labour and Welfare
-
2018/02/19
Takara Bio to Establish a New Facility for the Research and Manufacturing of Regenerative Medical Products
-
2018/01/19
First patient enrolled into phase I/II clinical trial of NY-ESO-1・siTCR gene therapy against synovial sarcoma in Japan
-
2017/12/21
Announcement on investigator-initiated clinical trial of neoadjuvant combination therapy with HF10 and Nivolumab
-
2017/11/06
Exclusive Global License for New Method of iPS Cell Production Obtained
読む Exclusive Global License for New Method of iPS Cell Production Obtained
-
2017/09/27
First patient enrolled into phase I clinical trial of Oncolytic Virus HF10 against pancreatic cancer in Japan
-
2017/06/01
Announcement on submission of the Clinical Trial Plan Notification for phase I clinical trial of Oncolytic virus HF10 against pancreatic cancer in Japan
-
2017/05/29
First patient enrolled into Oncolytic Virus HF10 phase II clinical trial in Japan
読む First patient enrolled into Oncolytic Virus HF10 phase II clinical trial in Japan
-
2017/05/23
Takara Bio presents HF10 Phase II clinical trial data at American Society of Clinical Oncology
読む Takara Bio presents HF10 Phase II clinical trial data at American Society of Clinical Oncology
-
2017/03/01
Takara Bio USA Holdings, Inc. completes acquisition of WaferGen Bio-systems, Inc.
読む Takara Bio USA Holdings, Inc. completes acquisition of WaferGen Bio-systems, Inc.
-
2017/01/30
Announcement on submission of the Clinical Trial Plan Notification for phase II clinical trial of Oncolytic virus HF10 in Japan
-
2017/01/24
Announcement on submission of the Clinical Trial Plan Notification for phase I/II clinical trial of NY-ESO-1・siTCR gene therapy in Japan
-
2017/01/18
Takara Bio USA Holdings, Inc. completes acquisition of Rubicon Genomics, Inc.
読む Takara Bio USA Holdings, Inc. completes acquisition of Rubicon Genomics, Inc.
-
2017/01/11
Announcement on submission of the Clinical Trial Plan Notification for phase I/II clinical trial of CAR gene therapy in Japan
-
2016/12/15
Takara Bio Signs Exclusive License Agreement with Otsuka for the Investigational Cancer Treatment HF10, an Oncolytic Virus
-
2016/12/15
Takara Bio USA Holdings, Inc. and Rubicon Genomics Announce Merger Agreement
読む Takara Bio USA Holdings, Inc. and Rubicon Genomics Announce Merger Agreement
-
2016/06/21
Takara Bio enters into a license and supply agreement of RetroNectin® with Kite Pharma
読む Takara Bio enters into a license and supply agreement of RetroNectin® with Kite Pharma
-
2016/05/19
Takara Bio presents HF10 Phase II clinical trial data at American Society of Clinical Oncology
読む Takara Bio presents HF10 Phase II clinical trial data at American Society of Clinical Oncology
-
2016/03/22
Takara Bio grants Cellectis SA a commercial license to use RetroNectin®
読む Takara Bio grants Cellectis SA a commercial license to use RetroNectin®
-
2016/02/02
Center for Gene and Cell Processing wins 2016 Facility of the Year Awards
読む Center for Gene and Cell Processing wins 2016 Facility of the Year Awards
-
2016/01/27
Establishment of a cell processing facility in “Life Innovation Center (provisional name)” in Tono-machi, Kawasaki city, as the implementation/ industrialization hub for cell therapy and regenerative medicine
-
2016/01/25
Release of GMP grade PCR enzyme for genetic diagnosis
-
2016/01/14
Notice of change in the Company Name, consolidated subsidiary, United States-based Clontech Laboratories, Inc.
-
2015/10/27
HF10 Phase II clinical trial data presented at AACR-NCI-EORTC international conference
読む HF10 Phase II clinical trial data presented at AACR-NCI-EORTC international conference
-
2015/09/29
Licensing agreement for manufacturing iPS cells using Sendai virus vector
読む Licensing agreement for manufacturing iPS cells using Sendai virus vector
-
2015/09/14
HF10 Phase I clinical trial data presented at European Society for Medical Oncology 2015 Congress
読む HF10 Phase I clinical trial data presented at European Society for Medical Oncology 2015 Congress
-
2015/08/10
Completion of a new facility and relocation of head office
読む Completion of a new facility and relocation of head office
-
2015/08/04
The 1st HF10 therapy in Japan was started against solid cancers
読む The 1st HF10 therapy in Japan was started against solid cancers
-
2015/07/24
Regenerative medicine based on dental pulp cells
-
2015/07/23
Takara Bio launches High-performance real-time PCR system
読む Takara Bio launches High-performance real-time PCR system
-
2015/06/17
Acquisition of ISO 9001 certification aiming at improvement in quality of products and services in regenerative medicine fields
-
2015/06/10
Patent regarding siTCR vector a core technique of gene therapy is granted in the U.S.
読む Patent regarding siTCR vector a core technique of gene therapy is granted in the U.S.
-
2015/06/01
Takara Bio launches culture medium specifically designed for iPS cells for research-use in regenerative medicine field
-
2015/05/19
Takara Bio is selected for ”Project Focused on Developing Key Evaluation Technology: Evaluation for Industrialization in the Field of Regenerative Medicine”
-
2015/05/13
Accreditation of the foreign cell processor: Takara Bio can start specific processed cell manufacturing and provide contracted cell processing service to medical institutions
-
2014/11/10
Acquisition of assets for stem cell-related research products from StemCells Inc.
読む Acquisition of assets for stem cell-related research products from StemCells Inc.
-
2014/11/04
License Agreement with iPS Academia Japan Inc.
-
2014/10/30
Takara Bio receives NEDO Grant to develop mass production of cardiomyocytes derived from human iPS cells
-
2014/10/27
License agreement for genome editing with Broad Institute
読む License agreement for genome editing with Broad Institute
-
2014/10/01
Marketing of Cellartis™ products started
-
2014/07/29
Acquisition of stem cell business firm (former Cellartis AB) from Cellectis SA
読む Acquisition of stem cell business firm (former Cellartis AB) from Cellectis SA
-
2014/06/24
Agreement with iHeart Japan Corporation
-
2014/05/30
Takara Bio reseives NEDO Grant to develop cell manufacturing and processing systems for industrialization of regenerative medicine
-
2014/05/08
Takara Bio Group’s Mid-term Management Plan
-
2014/05/01
Takara Bio submitted an Investigational New Drug application for a Phase II clinical trial of HF10 anti-cancer therapy to the Food and Drug Administration
-
2014/03/13
Clinical research protocol of gene therapy targeting B cell non-Hodgkin Lymphoma was approved by Japanese Ministry
-
2014/03/03
Takara Bio obtains a governmental grant for commercialization of its TCR gene therapy projects
読む Takara Bio obtains a governmental grant for commercialization of its TCR gene therapy projects
-
2014/02/10
Submission of the application for Investigator-initiated Phase I clinical trials of MAGE-A4 TCR gene therapy as Japan’s first genetic immunotherapy for cancer
-
2014/01/09
Takara Bio releases Mouse Feeder Cell Quantification Kit for quality control of human stem cells
読む Takara Bio releases Mouse Feeder Cell Quantification Kit for quality control of human stem cells
-
2013/12/02
Takara Bio launches new research reagents relating to the Adeno-Associated Virus Vector for gene transduction
-
2013/10/22
Clontech Releases the SMARTer Stranded RNA-Seq Kit
-
2013/09/30
Takara Bio expands the license agreement with iPS Academia Japan for new iPSC production technologies
-
2013/09/17
Takara Bio obtains a 94M JPY grant from the Japanese government for commercialization of its two regenerative medicines
-
2013/08/20
Takara Bio raises about JPY 11B through a public stock offer to invest for its gene therapy projects and for its new facilities
-
2013/07/25
Takara Bio distributes ZENOAQ’s cell cryopreservation medium in Japan, Europe, and North America
読む Takara Bio distributes ZENOAQ’s cell cryopreservation medium in Japan, Europe, and North America
-
2013/07/11
Takara Bio launches Nippi’s iMatrix-511 worldwide for robust proliferation of human stem cells
読む Takara Bio launches Nippi’s iMatrix-511 worldwide for robust proliferation of human stem cells
-
2013/06/24
Takara Bio Grants Cellular Dynamics International a Commercial License to Use RetroNectin® for iPSC Production
-
2013/06/13
Takara Bio grants Sun Toward Tech a license for mushroom production technology
読む Takara Bio grants Sun Toward Tech a license for mushroom production technology
-
2013/05/09
Takara Bio Group’s Mid-term Management Plan
-
2013/01/07
Takara Bio Announces Initiation of Phase 1 HIV Gene Therapy Clinical Trial
読む Takara Bio Announces Initiation of Phase 1 HIV Gene Therapy Clinical Trial
-
2012/11/21
Takara Bio grants license to Invivoscribe Technologies to use methods for detection of FLT3 mutations in Japan
-
2012/11/05
Takara Bio establishes a new manufacturing facility in Beijing to produce clinical grade antibodies for cell therapy
-
2012/11/01
Takara Bio Grants Bellicum Pharmaceuticals License to Use RetroNectin® for Gene Therapy
読む Takara Bio Grants Bellicum Pharmaceuticals License to Use RetroNectin® for Gene Therapy
-
2012/10/31
Takara Bio expands Phase I clinical trial for HF10 anti-cancer therapy to start multiple dosing study
-
2012/10/17
Exiqon and Takara Bio partners in the distribution of miRCURY LNA™ products in Asia
読む Exiqon and Takara Bio partners in the distribution of miRCURY LNA™ products in Asia
-
2012/09/27
Takara Bio launches new reagent for easy detection of the pluripotency for ES and iPS cells
読む Takara Bio launches new reagent for easy detection of the pluripotency for ES and iPS cells
-
2012/08/09
Takara Bio to establish a new facility for the research and manufacturing of pharmaceutical products for cell and gene therapies
-
2012/05/09
Announcement of Takara Bio Group’s mid-term management plan
読む Announcement of Takara Bio Group’s mid-term management plan
-
2012/03/19
Takara Bio Submitted an Investigational New Drug (IND) Application for HIV-1 Gene Therapy to the Food and Drug Administration (FDA)
-
2011/10/31
Takara Bio to initiate a clinical development of gene therapy targeting non-Hodgkin lymphoma
読む Takara Bio to initiate a clinical development of gene therapy targeting non-Hodgkin lymphoma
-
2011/07/27
Starting up the gene therapy project in China
-
2011/04/27
Announcement of Takara Bio’s mid-term management plan
-
2011/02/15
Takara Bio to establish a subsidiary for manufacturing and sales of research reagents in India
読む Takara Bio to establish a subsidiary for manufacturing and sales of research reagents in India
-
2010/10/22
Takara Bio to acquire anti-cancer drug business from M’s Science
読む Takara Bio to acquire anti-cancer drug business from M’s Science
-
2010/04/30
Takara Bio Grants QIAGEN a license for LA-PCR Technology
-
2010/03/11
Takara Bio to Enter into a Collaborative Research Agreement with University of Pennsylvania, Aiming for a Future Clinical Trial of HIV Gene Therapy
-
2009/06/17
Takara Bio Inc. to supply RetroNectin® to U.S. and Europe for multicentre clinical trials of gene therapy targeting X-linked Severe Combined Immunodeficiency (X-SCID)
-
2009/06/04
Takara Bio and Kohjin-bio form an alliance in the field of cell culture media
読む Takara Bio and Kohjin-bio form an alliance in the field of cell culture media
-
2009/05/12
Announcement of Takara Bio's mid-term management plan
-
2009/04/22
National Cancer Center in Japan gains a regulatory approval of the clinical research for HSV-TK “haplo add-back” gene therapy in treatment of leukemia